Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 1Recurrence 1Leukemia, Myeloid, Acute 1GATA2 Deficiency 1Carcinoma, Neuroendocrine 1

Interventions

Everolimus 7Nivolumab 6Cisplatin 6Temozolomide 5Bevacizumab 5lutetium Lu 177 dotatate 4Fluorouracil 4Carboplatin 4pembrolizumab 3avelumab 3atezolizumab 3Irinotecan 3Ipilimumab 3Etoposide 3Capecitabine 3surufatinib 2sintilimab 2gallium Ga 68 dotatate 2dostarlimab 2Radiosurgery 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2PE regimen 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Magnetic Resonance Imaging 2Immunoglobulin G 2IFL protocol 2Fluorodeoxyglucose F18 2Drug Therapy 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Neuroendocrine × iadademstat × Clear all
NCT05420636 2025-07-30

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Fox Chase Cancer Center

Phase 2 Terminated
20 enrolled
EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡